CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
risankizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05283135
NCT05283135Phase 2Completed
CompareCT.gov

Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis

Oregon Medical Research Center·interventional·Posted Mar 16, 2022·Updated Oct 24, 2025

In Brief

A Phase 2 clinical trial evaluating risankizumab for Psoriasis. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This pilot study explores higher than standard doses of risankizumab for plaque psoriasis, to see effects on resident memory T cells and skin clearance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMar 16, 2022
Enrollment StartMar 1, 2022
Primary CompletionAug 7, 2023
Study CompletionJul 10, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.3 years ago

Interventions

risankizumabdrug

Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.